Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
| 1.1 | |
| 1.1 | |
| - | |
| 1.1 | |
| 1.1 | |
| 0.35-1.58 | |
| 324 M | |
| 256 M | |
| 18 358 K | |
| -0.1064 | |
| 2.301 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
On December 1, 2023, Baillie Gifford (Trades, Portfolio), a renowned investment management firm, expanded its investment portfolio by adding a significant number of shares in Adaptimmune Therapeutics ...
This month, we saw the Adaptimmune Therapeutics plc (NASDAQ:ADAP) up an impressive 58%. But only the myopic could ignore the astounding decline over three years. Indeed, the share price is down a whop...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
